Axogen cites ongoing advantages for Avance Nerve Graft
Axogen, Inc. presented at a November 9 investor event to highlight the clinical benefits and surgical technique of its Avance nerve graft, stating a prostate market launch remains under consideration.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed